£230m · Series C · Healthtech · Oxford, UK
Oxford-based OMass Therapeutics has closed an oversubscribed £230m Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. The company’s 15 October announcement values the round at $310m (£230m) and says Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences joined alongside all existing investors.
The capital is meant to take lead programme OMS1620 through Phase 2 development in congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. It will also support initial clinical data for an SLC15A4 inhibitor aimed at lupus and other diseases linked to interferon overproduction and pathogenic B-cell activation.
A large round tied to two clinical readouts
OMS1620 is designed to block the MC2 receptor, the route through which ACTH stimulates adrenal hormone production. OMass says the molecule has been engineered to remain active as endogenous ACTH rises, with the goal of helping patients control excess androgen production while staying on physiological glucocorticoid doses. That proposed profile still has to be demonstrated in larger clinical studies; the Series C finances the programme through the Phase 2 test where efficacy, dosing and safety become much more consequential.
The second programme creates another clinical proof point rather than merely extending the discovery pipeline. OMass plans to generate early human data for its SLC15A4 inhibitor, which is intended to interfere with immune signalling implicated in lupus. Forbion’s Audrey Cacaly said the financing could deliver clinical data from both programmes, offering a test of whether OMass’s internally discovered candidates can translate into differentiated medicines.
The platform now has to prove itself in patients
OMass was spun out of Professor Dame Carol Robinson’s University of Oxford laboratory. Its OdyssION platform combines native mass spectrometry, biochemistry and custom chemistry to study drug targets in their native molecular environments. The commercial premise is that preserving those surrounding interactions can expose binding sites and drug behaviour that conventional isolated-target methods miss.
The company has now moved from discovery into clinical development. That changes the value question behind the platform: finding difficult targets and producing candidates is no longer enough on its own. The financing gives OMass the resources to test whether those candidates show meaningful effects in patients, while two programmes provide separate evidence about the platform’s productivity. The next milestones are therefore specific clinical datasets, not the size of the round itself.
Sources checked:
OMass company announcement · GlobeNewswire distributed release · Tech.eu Funding Explorer
